Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13852888 | 1.00 | ERAP2 (0.56) | ERAP2ERAP1ANPEPGHSRMEN1 | |
| SCHEMBL13852889 | 0.94 | GHSR (0.56) | ERAP2ERAP1ANPEPGHSR | |
| SCHEMBL13852890 | 0.94 | GHSR (0.56) | ERAP2ERAP1ANPEPGHSR | |
| SCHEMBL8259873 | 0.88 | ERAP2 (0.52) | ERAP2ERAP1ANPEPGHSRMEN1 | |
| SCHEMBL8251294 | 0.88 | ERAP2 (0.52) | ERAP2ERAP1ANPEPGHSRMEN1 | |
| SCHEMBL12433268 | 0.86 | TACR1 (0.53) | ERAP2ERAP1ANPEP | |
| SCHEMBL13853026 | 0.86 | GHSR (0.59) | ERAP2ERAP1ANPEPGHSR | |
| SCHEMBL12511244 | 0.86 | GHSR (0.59) | ERAP2ERAP1ANPEPGHSR | |
| SCHEMBL12433272 | 0.86 | GHSR (0.59) | ERAP2ERAP1ANPEPGHSR | |
| SCHEMBL12433274 | 0.86 | GHSR (0.59) | ERAP2ERAP1ANPEPGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981922-B2 | Angiotensin I-converting enzyme (ACE) inhibitors | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-19 | — | — | US | disclosed |
| US-20090118351-A1 | Angiotensin I-Converting Enzyme (ACE) Inhibitors | ANGIODESIGN (UK) LIMITED (GB) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118351-A1 | Angiotensin I-Converting Enzyme (ACE) Inhibitors | ACE, ACE2, DNPEP | ERAP2 33/4885ERAP1 25/4885ANPEP 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.